NSG-engrafting AMLs produce a lymphoid graph in NOD/SCID IL2Rγc^null mice. BM cells from (A) AML- (AML#2), (B) T-ALL-, and (C) NSG-engrafting AML (AML#23)-transplanted NOD/SCID β2^−/− and NOD/SCID IL2Rγc^null mice were analyzed by flow cytometry. Surface expression of myeloid-cell (CD33 and CD13 inside CD45-positive population), B-cell (CD19 inside CD45-positive population) and T-cell (CD3, and CD4/CD8 inside CD3+ population) markers is represented. Phenotype of de novo isolated (A) AML, (B) T-ALL, and (C) NSG-AML is represented in the left panel. (D) Summary of the human graft composition (inside human CD45-positive population) in BM (left) and spleen (right) of AML-transplanted NOD/SCID IL2Rγc^null mice. Myeloid, B and T cells are defined by the expression of CD13/CD33; CD19; and CD3, respectively. Black indicates NSG-AML samples; and white, AML samples. Each symbol represents a specific AML sample. Individual mice are graphed. NSG-AML: AML#22, #23, #24; 9 mice. AML: AML#2, #4, #5, #6, #11, #20, #21; 22 mice. ***P ≤ .00001.